Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Ming Lu, PhD, Chenhui Deng, PhD, Yifeng Xiong, PhD, Hengbang Wang, Ping Xu, PhD, Lichuang Men, Tanhong Xie, Qian Jiang, MD, Zi Chen, MD, Qian Niu, MD, Ping Liu, PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141268

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Wenbing Duan, Xiaohong Liu, Jinsong JIA, MDPhD, Jing Wang, MD, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaosu Zhao, PhD, Yazhen Qin, Hongxia Shi, Yingjun Chang, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141905

Published: 2020

Journal Articles

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study

Delphine Rea, MDPhD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Qian Jiang, MD, Katia B Pagnano, MDPhD, Matilda Ongondi, MD, Chung Hoow Kok, BSc, PhD, Nicola Evans, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, International CML Foundation

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140161

Published: 2020

Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-142142

Published: 2020

Journal Articles

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, MD, Qian Jiang, MD

Blood (2019) 134 (Supplement_1): 2940.

https://doi.org/10.1182/blood-2019-130081

Published: 2019

Journal Articles

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3 rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, Lichuang Men, Hengbang Wang, PhD, Jiao JI, PhD MD, Bo Huang, Dayu Shi, Ting Zhao, Yue Hou, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 493.

https://doi.org/10.1182/blood-2019-124295

Published: 2019

Journal Articles

Dead/H-Box Helicase 11 ( DDX11 ) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice

Blood (2019) 134 (Supplement_1): 2732.

https://doi.org/10.1182/blood-2019-127831

Published: 2019

Journal Articles

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Wenbing Duan, Jinsong Jia, Jing Wang, MD, Xiaohong Liu, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, MD, Lanping Xu, Yanrong Liu, Yazhen Qin, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 2616.

https://doi.org/10.1182/blood-2019-126938

Published: 2019

Journal Articles

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Blood (2019) 134 (Supplement_1): 1421.

https://doi.org/10.1182/blood-2019-127937

Published: 2019

Journal Articles

Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?

Ya-Lan Zhou, MD, Li-Xin Wu, Robert Peter Gale, Run-Qing Lu, Jin-Lan Li, Hao Jiang, Qian Jiang, MD, Bin Jiang, Zi-Long Wang, Ting-Ting He, Yue Wang, Xiao-Xiao Zhang, Xiaohui Zhang, MD, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Guorui Ruan

Blood (2018) 132 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2018-99-116592

Published: 2018

Journal Articles

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Blood (2018) 132 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2018-99-119402

Published: 2018

Journal Articles

Osteoclast Stimulatory Transmembrane Protein ( OCSTAMP ) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma

Ya-Lan Zhou, MD, Jin Lu, Robert Peter Gale, Shen-Miao Yang, Li-Xin Wu, Jin-Lan Li, Ya-Zhen Qin, Yan-Rong Liu, Hao Jiang, Qian Jiang, MD, Xiaohui Zhang, MD, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Guorui Ruan

Blood (2018) 132 (Supplement 1): 5264.

https://doi.org/10.1182/blood-2018-99-116883

Published: 2018

Journal Articles

Safety and Efficacy of HQP1351, a 3 rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study

Qian Jiang, MD, Xiao Jun Huang, Zi Chen, MD, Lichuang Men, Wei Liu, Xuemei Sun, Jiao JI, PhD MD, Hengbang Wang, Yue Hou, Po Hu, Lei Zou, Hua Yan, Yingjie Huang, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2018) 132 (Supplement 1): 791.

https://doi.org/10.1182/blood-2018-99-119142

Published: 2018

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

Recombinant Human Thrombopoietin Increases Platelet Numbers and Reduces the Risk of Bleeding Events in Thrombocytopenic Patients with Chronic Hepatitis B Virus Infection: A Multicenter Observational Study

Blood (2018) 132 (Supplement 1): 4990.

https://doi.org/10.1182/blood-2018-99-116000

Published: 2018

Journal Articles

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Lu Yu, MD, Qian Jiang, MD

Blood (2017) 130 (Supplement 1): 1605.

https://doi.org/10.1182/blood.V130.Suppl_1.1605.1605

Published: 2017

Journal Articles

Mutation Topology of Adult B-Cell Acute Lymphoblastic Leukaemia

Li-Xin Wu, Run-Qing Lu, Kai-Yan Liu, Robert Peter Gale, MD ScD, PhD, Qi Zheng, Jiao Zhou, Jin-Lan Li, Shu-Juan Wang, Hao Jiang, MD, Qian Jiang, MD, Bin Jiang, Xiao-Hui Zhang, MD, Lan-Ping Xu, Yue Wang, Cheng-Li Song, Ya-Zhen Qin, Yan-Rong Liu, Xiao-Jun Huang, MD, Guo-Rui Ruan

Blood (2017) 130 (Supplement 1): 3986.

https://doi.org/10.1182/blood.V130.Suppl_1.3986.3986

Published: 2017

Journal Articles

Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors

Qian Jiang, MD, Lu Yu, MD, Ya-Zhen Qin, Yue-Yun Lai, Xiao-Jun Huang, MD

Blood (2017) 130 (Supplement 1): 2876.

https://doi.org/10.1182/blood.V130.Suppl_1.2876.2876

Published: 2017

Journal Articles

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Qian Jiang, MD, Lu Yu, Robert Peter Gale, MD PhD DSc

Blood (2016) 128 (22): 3092.

https://doi.org/10.1182/blood.V128.22.3092.3092

Published: 2016

NARROW

Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3 rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Dead/H-Box Helicase 11 ( DDX11 ) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Osteoclast Stimulatory Transmembrane Protein ( OCSTAMP ) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma

Safety and Efficacy of HQP1351, a 3 rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Recombinant Human Thrombopoietin Increases Platelet Numbers and Reduces the Risk of Bleeding Events in Thrombocytopenic Patients with Chronic Hepatitis B Virus Infection: A Multicenter Observational Study

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Mutation Topology of Adult B-Cell Acute Lymphoblastic Leukaemia

Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors

Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only